|
 |
Dear Colleague,
Fortis Clinical Research Ltd. (FCRL) is a Contract Research Organization (CRO) based in Faridabad, suburbs of Delhi. It was established in 2005 and in the initial years specialized in Bioequivalence studies in healthy volunteers. Since Jan 2006 FCRL has completed over 250 Bioequivalence studies for generic (multi source) pharmaceutical products.
|
The BE study reports have been submitted by the sponsors to Australia, Brazil, Canada, EU countries (Finland, France Spain, Denmark, Norway, Ireland, Italy, Poland, Portugal, Germany, Hungary, Ireland, Netherlands etc), India, Malaysia, South Africa, UK and USA. FCRL have been approved by AFSAAPS (France), ANVISA (Brazil) and DCGI (India). Till date we have carried out four pivotal bio-studies for US-FDA submission. FCRL is recognized by Department of Science & Industrial Research, Govt. of India as an approved Research & Development Company.
Considering the many advantages that the large network of Fortis Escorts Hospitals with their excellent infrastructure and presence of renowned clinicians of international repute can bring to clinical research, FCRL would harness these advantages besides the large pool of treatment naïve patients and excellent follow up that Fortis Escorts Hospitals have in place, to help organize and manage global multi-centre clinical trials in all therapeutic areas. Renowned clinicians, both from academic institutions and from private practice have agreed to serve on advisory panel for their respective therapeutic areas.
A state of the art clinical research facility suitable for Phase I and Phase 0 clinical trials besides additional beds for bio-studies would soon be available in the Pink City.
With our harmonious integrated working relationship with College of American Pathologists certified Clinical Reference Laboratory and with the excellent guidance provided by our advisory board, FCRL looks forward to providing reliable, quality assured, on time service with a smile. At FCRL we provide world class service at Indian prices and hope to become CRO of choice for drug development efforts of global pharmaceutical industry. |
|
|
|
|
